Last reviewed · How we verify
NCT03032770
Early Prediction of Placenta Accreta by Ultrasound and Color Doppler
trial testing two-dimensional ultrasound and color Doppler in Placenta Accreta in 148 participants. Completed in 31 March 2020.
31 December 2019
Quick facts
| Lead sponsor | Assiut University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 148 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 March 2020 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- two-dimensional ultrasound and color Doppler
Conditions studied
- Placenta Accreta — all drugs for Placenta Accreta →
Sponsor
Assiut University
Who can join
Eligibility, female only, with Placenta Accreta. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Placenta accreta is a substantially life threatening condition and one of the causes of maternal morbidity and mortality in the world. According to study done in United Kingdom, The estimated incidence of placenta accreta/increta/percreta was 1.7 per 10,000 maternities overall and 577 per 10,000 in women with both a previous cesarean delivery and placenta previa. in a tertiary south Italian center, The incidence increased from 0.12% during the 1970s, to 0.31% during the 2000s.While in United States of America, the prevalence of placenta accreta was 3.7 per 1000 deliveries.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03032770
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Placenta Accreta
Currently open trials in the same condition.
- NCT07283042 — Evaluation of Clinical Outcomes and Acceptability of an Anatomical Classification for Placenta Accreta Spectrum · recruiting
- NCT06465836 — Simplified Conservative Measures in Managing Morbidly Adherent Placenta in Beni-Suef University · NA · recruiting
- NCT06185894 — Single-step Placenta Accreta Resective Technique Tourniqueted vs Absence, Conservative Uterine Surgery · NA · recruiting
- NCT06833606 — Diagnosis and Outcomes of Placental Accretism · recruiting
- NCT05922397 — Placenta Accreta Spectrum Topographic Classification · recruiting
Other Assiut University trials
Trials by the same sponsor.
- NCT07423312 — Lead Exposure and Multiple Sclerosis · not yet recruiting
- NCT07234526 — Usage of Glucose Fluctuations as a Prognostic Marker in Septic Shock Patients · not yet recruiting
- NCT07273214 — Knowledge, Attitude and Practice of Third Trimester Pregnant Mothers Towards Self-Medication in Assiut, Egypt · not yet recruiting
- NCT07194863 — Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD · not yet recruiting
- NCT07053709 — Screening for Hyperuricemia in Patients With Metabolic Associated Fatty Liver Disease (MAFLD) · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03032770 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assiut University
- Last refreshed: 13 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03032770.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing